Abstract
The renin–angiotensin system regulates blood pressure and sodium homeostasis through a series of coordinated substrate–enzyme interactions. These interactions result in the production of angiotensin II (AII), which exerts a number of diverse biologic effects mediated through AII cell‐surface receptors. Dysregulation of this system is implicated in the pathogenesis of various forms of hypertension. Traditional therapy for hypertension has included angiotensin‐converting enzyme inhibitors, which block the production of AII. However, a new class of drugs, AT1‐receptor blockers, now offers a number of benefits by specifically blocking the effects of AII at its physiologically relevant receptor.
Keywords: hypertension, renin–angiotensin system, angiotensinogen, angiotensin II, AT1 receptor, AT1‐receptor blocker, losartan
Full Text
The Full Text of this article is available as a PDF (385.1 KB).
References
- 3. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P: Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992; 71: 169–180 [DOI] [PubMed] [Google Scholar]
- 4. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jeannette JC, Coffman TM, Maeda N, Smithies O: Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2735–2739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Hilbert P, Lindpaintner K, Beckmann JS, Serikawa T, Soubrier F, Dubay C, Cartwright P, De Gouyon B, Julier C, Takahasi S: Chromosomal mapping of two genetic loci associated with blood pressure regulation in hereditary hypertensive rats. Nature 1991; 353: 521–529 [DOI] [PubMed] [Google Scholar]
- 6. Jacob HJ, Lindpaintner K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, Ganten D, Dzau VJ, Lander ES: Genetic mapping of a gene causing hypertension in the stroke prone spontaneously hypertensive rat. Cell 1991; 67: 213–224 [DOI] [PubMed] [Google Scholar]
- 7. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161–1172 [DOI] [PubMed] [Google Scholar]
- 8. Guyton A: Abnormal renal function and autoregulation in essential hypertension. Hypertension 1991; 18 (suppl III): 49–53 [DOI] [PubMed] [Google Scholar]
- 9. Hall J: Control of sodium excretion by angiotensin II: Intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986; 250: R960–R972 [DOI] [PubMed] [Google Scholar]
- 10. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–251 [PubMed] [Google Scholar]
- 11. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin receptor reveals a unique class of seven‐transmembrane domain receptors. J Biol Chem 1993; 268 (33): 24539–24542 [PubMed] [Google Scholar]
- 12. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268: 24543–24546 [PubMed] [Google Scholar]
- 13. Murphy TJ, Takeuchi K, Alexander RW: Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 1992; 5: 236S–242S [DOI] [PubMed] [Google Scholar]
- 14. Gasc J‐M, Shanmugam S, Sibony M, Corvol P: Tissue‐specific expression of type I angiotensin II subtypes. An in situ hybridization study. Hypertension 1994; 24: 531–537 [DOI] [PubMed] [Google Scholar]
- 15. Burson JM, Aguilera G, Gross KW, Sigmund CD: Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 1994; 267: E260–E267 [DOI] [PubMed] [Google Scholar]
- 16. Llorens‐Cortes C, Greenberg B, Huang H, Corvol P: Tissular expression and regulation of type I angiotensin II receptor subtypes by quantitative reverse transcriptase‐polymerase chain reaction analysis. Hypertension 1994; 24: 538–548 [DOI] [PubMed] [Google Scholar]
- 17. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM: Regulation of blood pressure by the type 1A receptor for angiotensin II. Proc Natl Acad Sci USA 1995; 92: 3521–3525 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin‐converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–795 [DOI] [PubMed] [Google Scholar]
- 19. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB: Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 755: 405–411 [PubMed] [Google Scholar]
- 20. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo‐controlled, double‐blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345–1350 [DOI] [PubMed] [Google Scholar]
- 21. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP, Nelson EB, Losartan Cough Study Group: Effects of modulators of the renin‐angiotensin‐aldosterone system on cough. J Hypertens 1994; 12: 1387–1393 [PubMed] [Google Scholar]